



(12) **United States Patent**  
**Graham et al.**

(10) **Patent No.:** **US 9,410,154 B2**  
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **HBV TREATMENT**

FOREIGN PATENT DOCUMENTS

(71) Applicant: **BENITEC BIOPHARMA LIMITED**,  
Balmain, New South Wales (AU)

CN 101684478 A 3/2010  
CN 101979556 A 2/2011

(72) Inventors: **Michael Wayne Graham**, Jindalee (AU); **Peter French**, Balmain (AU); **York YuanYuan Zhu**, Palo Alto, CA (US); **YiXiang Lu**, Jiangshu (CN); **TieJun Li**, Jiangshu (CN); **YunCheng Sun**, Jiangshu (CN); **XiaoJun Tang**, Jiangshu (CN); **Li Shan**, Laval (CA)

OTHER PUBLICATIONS

Grimm, et al. 2007 "Combinatorial RNAi: A winning strategy for the race against evolving targets?" *Molecular Therapy* 15: 878-888.

Li, Z. et al. 2009 "Inhibition of HBV replication and gene expression in vitro and in vivo with a single AAV vector delivering two shRNA molecules" *BMB Reports* 42: 59-64.

Romano, P.R. et al. 2006 "RNA interference-mediated prevention and therapy for hepatocellular carcinoma" *Oncogene* 25: 3857-3865.

Snyder, L.L. et al. 2009 "RNA Polymerase III can drive polycistronic expression of functional interfering RNAs designed to resemble microRNAs" *Nucleic Acids Research* 37: e127 (10 pages).

Supplemental European Search Report, in European Application No. 11 83 5635, dated Mar. 14, 2014.

Tang, Tong-Yu 2009 "Inhibition of HBV with RNAi based on microRNA" Chinese Doctoral Dissertations Full-text Database Medicine and Health Sciences, Aug. 15, 2009, year 2009, No. 8, p. E061-2.

Weinberg, M.S. et al. 2007 "Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA" *Molecular Therapy* 15(3): 534-541.

Wu, K.-L. et al. 2005 "Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment" *Virus Research* 112: 100-107.

Ji, et al. 2003 "Enhanced gene silencing by the application of multiple specific small interfering RNAs" *FEBS Letters* 552: 247-252.

Radulovich, et al. 2011 "Modified gateway system for double shRNA expression and Cre/lox based gene expression" *BMC Biotechnology* 11: 24 (in 9 pages).

Schuck, et al. 2004 "Generation of single and double knockdowns in polarized epithelial cells by retrovirus-mediated RNA interference" *Proceedings of the National Academy of Sciences* 101(14): 4912-4917.

Yu, et al. 2003 "Simultaneous inhibition of GSK3 $\alpha$  and GSK3 $\beta$  using hairpin siRNA expression vectors" *Molecular Therapy* 7(2): 228-236.

*Primary Examiner* — Kimberly Chong

(74) *Attorney, Agent, or Firm* — Fenwick & West LLP

(73) Assignee: **BENITEC BIOPHARMA LIMITED**,  
Balmain, New South Wales (AU)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/731,824**

(22) Filed: **Jun. 5, 2015**

(65) **Prior Publication Data**

US 2015/0344885 A1 Dec. 3, 2015

**Related U.S. Application Data**

(63) Continuation of application No. 13/882,124, filed as application No. PCT/CN2011/081386 on Oct. 27, 2011, now Pat. No. 9,080,174, which is a continuation of application No. PCT/CN2011/071107, filed on Feb. 18, 2011.

(30) **Foreign Application Priority Data**

Oct. 28, 2010 (CN) ..... 2010 1 0521948  
Oct. 28, 2010 (CN) ..... 2010 1 0521962  
Oct. 28, 2010 (CN) ..... 2010 1 0521972  
Oct. 28, 2010 (CN) ..... 2010 1 0521975  
Oct. 28, 2010 (CN) ..... 2010 1 0521990  
Oct. 28, 2010 (CN) ..... 2010 1 0522003  
Oct. 28, 2010 (CN) ..... 2010 1 0522005

(57) **ABSTRACT**

RNA interference (RNAi) agents and the use of the RNAi agents for treating hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents are provided. The RNAi agents, or constructs for expressing them are utilized to inhibit expression of at least one Hepatitis B virus (HBV) gene, wherein each agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some embodiments of the present invention, the agents have more than one effector sequence; wherein the multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

(51) **Int. Cl.**  
**C07H 21/04** (2006.01)  
**C12N 15/113** (2010.01)

(52) **U.S. Cl.**  
CPC ..... **C12N 15/1131** (2013.01); **C12N 2310/14** (2013.01); **C12N 2310/531** (2013.01)

(58) **Field of Classification Search**  
None  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2003/0206887 A1 11/2003 Morrissey et al.  
2006/0189561 A1 8/2006 Roelvink et al.

**20 Claims, 13 Drawing Sheets**